aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Limerick BioPharma is a US-based developer of biopharmaceutical products focused on treating solid organ transplantation and metabolic diseases. The company offers compounds addressing metabolic dysregulation caused by leading immunosuppressants and conditions like diabetes and dyslipidemia.
Limerick BioPharma has made significant strides in the biopharmaceutical industry, contributing to advancements in treatments for complex medical conditions. Their innovative approach has positioned them as a key player in the field, impacting patient care and therapeutic options.
Operating Status
Closed
Ownership Type(s)
Private
Main Product(s)
Biopharmaceuticals
Technology
Biotech
Tags
SaaS
Model Types
Recurring
Customer Type(s)
Enterprise, Government
Geographic Exposure
United States
When was Limerick BioPharma founded?
Limerick BioPharma was founded in 2004.
Where is Limerick BioPharma’s headquarters located?
Limerick BioPharma’s headquarters is located in South San Francisco, CA, US.
When was Limerick BioPharma’s last funding round?
Limerick BioPharma’s most recent funding round was for $480k (USD) in January 2012.
How many employees does Limerick BioPharma have?
Limerick BioPharma has 30 employees as of Feb 5, 2024.
How much has Limerick BioPharma raised to-date?
As of July 05, 2023, Limerick BioPharma has raised a total of $47.1M (USD) since Jan 30, 2012.
Add Comparison
Total Raised to Date
$47.1M
USD
Last Update Jan 30, 2012
Last Deal Details
$480k
USD
Jan 30, 2012
Debt Financing
Total Employees Over Time
30
As of Feb 2024
Limerick BioPharma Address
601 Gateway Blvd
suite 700
South San Francisco,
California
940807031
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts